<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841345</url>
  </required_header>
  <id_info>
    <org_study_id>38RC11.210</org_study_id>
    <nct_id>NCT02841345</nct_id>
  </id_info>
  <brief_title>Characterization of Emotional Processing of Information in Bipolar Disorder and Schizophrenic Patients</brief_title>
  <acronym>EMOBISCHI</acronym>
  <official_title>Characterization of Emotional Processing of Information in Bipolar Disorder and Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the case of psychotic disorders such as bipolar disorder or schizophrenia, attention&#xD;
      dysfunction contribute, according to the theories of neuroscience, the development of mood&#xD;
      disorders following disturbances in the interaction-care emotion. In this context, the&#xD;
      general objective of this research project is to refine our understanding of the similarities&#xD;
      and distinctions between bipolar and schizophrenic patients in the basic emotional&#xD;
      information processing. Specifically, these are: 1) to better understand what level of basic&#xD;
      emotional information processing both conditions differ or are comparable and in what sense&#xD;
      and 2) estimate, in both pathologies, the specific influence of the nature of the task of&#xD;
      processing emotional information. To answer these questions, the investigators have developed&#xD;
      a protocol to specifically target different information processing channels playing on the&#xD;
      nature of the spatial frequency content of emotional natural scenes. To estimate in both&#xD;
      pathologies, the specific influence of the nature of the task on emotional processing, 3&#xD;
      types of tasks are proposed: 1) a simple task perception and 2) -3) two tasks whose&#xD;
      categorization one focused on the emotional feelings of the individual and the other on the&#xD;
      tendency to action. Both tasks categorization should involve more specifically the&#xD;
      ventromedial prefrontal cortex (CPFVM) and the dorsolateral prefrontal cortex (DLPFC)&#xD;
      respectively. All patient data will be compared with data from healthy control participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main goals This research project generally aims to refine our understanding of the&#xD;
      similarities and distinctions between bipolar and schizophrenic patients in emotional&#xD;
      information processing.&#xD;
&#xD;
      Specifically, these are:&#xD;
&#xD;
        1. better understand what level of emotional information processing both conditions differ&#xD;
           or are comparable and in what direction&#xD;
&#xD;
        2. assess specifically in both pathologies, emotional regulation deficits through the&#xD;
           realization of different cognitive tasks when processing emotional information.&#xD;
&#xD;
      To answer these questions, the investigators developed an original protocol imaging&#xD;
      functional magnetic resonance (fMRI) to specifically target different information processing&#xD;
      channels playing on the nature of the spatial frequency content of emotional natural scenes&#xD;
      (see Methods). emotional regulation deficits in both disorders will be addressed in part&#xD;
      through here 3 types of tasks: 1) a simple task perception and 2) -3) two tasks&#xD;
      categorization of which centered on the emotional feelings of the individual (task affective)&#xD;
      and the tendency to action (motivational task). Both tasks categorization should involve more&#xD;
      specifically the Prefrontal Cortex-Ventro Median (CPFVM) and Lateral Prefrontal Cortex-Dorso&#xD;
      (DLPFC), respectively, distinguishing between the two categories of patients. All patient&#xD;
      data will be compared to healthy control participants.&#xD;
&#xD;
      This project will also allow us to improve our knowledge in bipolar and schizophrenic&#xD;
      patients compared with control subjects, i) on the brain structures of networks involved in&#xD;
      emotional information processing and emotional regulation, ii) functional relationships still&#xD;
      unclear between neural structures involved in both processes and iii) the nature of the&#xD;
      information passing through these networks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">February 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric evaluation</measure>
    <time_frame>70 minutes</time_frame>
    <description>PANSS - POSITIVE AND NEGATIVE SYNDROME SCALE Scale with 30 items</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychometric evaluation</measure>
    <time_frame>15 minutes</time_frame>
    <description>MADRS - Montgomery Asberg Depression Rating</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychometric evaluation</measure>
    <time_frame>15 minutes</time_frame>
    <description>YMRS - Young Mania Rating Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-Questionnaire</measure>
    <time_frame>Few hours</time_frame>
    <description>SHAPS - Snaith-Hamilton Pleasure Scale Starkstein STAI Y - State-Trait Anxiety Inventory AIM: &quot;affect intensity measure&quot; ALS: &quot;affective lability scale&quot; MATHYS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive questionnaire</measure>
    <time_frame>15 minutes</time_frame>
    <description>CPT II - Conners' Continuous Performance Test II</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Bipolar</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>bipolar patients type I or II (DSM-IV TR), euthymic phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schizophrenic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>schizophrenic loss or paranoid or undifferentiated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>control group (paired in age and sex for patients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>behavioral and fMRI</intervention_name>
    <description>The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.&#xD;
In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.&#xD;
In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.&#xD;
In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants.</description>
    <arm_group_label>Bipolar</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Schizophrenic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        healthy volunteers&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Informed Consent signed&#xD;
&#xD;
          -  Medical examination conducted before research participation&#xD;
&#xD;
          -  Age, sex and level of education paired with bipolar and schizophrenic patients)&#xD;
&#xD;
          -  French Language and Culture&#xD;
&#xD;
          -  normal or corrected vision and hearing to normal&#xD;
&#xD;
          -  affiliate Obligation to social security&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Topic included in an ongoing experiment&#xD;
&#xD;
          -  contraindication to MRI (metal hardware or electronic incompatible with MRI&#xD;
             examination, permanent glasses, braces, Claustrophobia, cardiac or neurological&#xD;
             stimulator, Clip unsecured vascular nonmagnetic metal Eclat)&#xD;
&#xD;
          -  Important Hearing Disorders and vision&#xD;
&#xD;
          -  neurological pathologies or past or current neuropsychiatric&#xD;
&#xD;
          -  Family history of psychiatric disorders&#xD;
&#xD;
          -  Drug treatment may modulate brain activity: benzodiazepines, antidepressants,&#xD;
             neuroleptics, etc.&#xD;
&#xD;
          -  Alcohol Ingestion&#xD;
&#xD;
          -  Pregnant women, women in labor, nursing mother&#xD;
&#xD;
          -  All other categories of protected persons&#xD;
&#xD;
        bipolar patients&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Informed Consent signed&#xD;
&#xD;
          -  Review medical and psychiatric assessment and inclusion made before participation in&#xD;
             research&#xD;
&#xD;
          -  Membership or beneficiary of a social security scheme&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Language and French culture&#xD;
&#xD;
          -  study BAC level or equivalent&#xD;
&#xD;
          -  normal or corrected vision and hearing to normal&#xD;
&#xD;
          -  Inpatient and outpatient&#xD;
&#xD;
          -  Diagnosis of bipolar disorder type I and II DSM-IV TR (A.P.A 1994)&#xD;
&#xD;
          -  Clinical Stability (inter-Critical) for at least three months with scores of ladders&#xD;
             MADRS &lt;15 and YMRS &lt;12.&#xD;
&#xD;
          -  In case of anxiety symptoms, prescription Cyanemazine® or Hydroxyzine® be allowed, at&#xD;
             low doses (&lt;75 mg cyamemazine and hydroxyzyne).&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Patient Refusal&#xD;
&#xD;
          -  Diagnosis of bipolar disorder with rapid cycling and mixed episodes&#xD;
&#xD;
          -  psychiatric pathology addictive disorder or schizophrenia / schizoaffective&#xD;
&#xD;
          -  neurological pathologies or progressive neurosurgical&#xD;
&#xD;
          -  Personal history of seizures&#xD;
&#xD;
          -  Treatment with electroconvulsive therapy (ECT) in the 6 months preceding the&#xD;
             assessment.&#xD;
&#xD;
          -  Patients hospitalized under stress or under legal protection measure (guardianship,&#xD;
             curatorship)&#xD;
&#xD;
          -  Subject deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Contraindications to the practice of MRI equipment or incompatible metal or electronic&#xD;
             foreign body with MRI examination, permanent glasses, braces, Claustrophobia, cardiac&#xD;
             or neurological stimulator, Clip unsecured vascular nonmagnetic metal Eclat)&#xD;
&#xD;
          -  significant disorders of hearing and vision&#xD;
&#xD;
          -  Alcohol Ingestion&#xD;
&#xD;
          -  Pregnant women, women in labor, nursing mother&#xD;
&#xD;
        schizophrenic patients&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Informed Consent signed&#xD;
&#xD;
          -  Review medical and psychiatric assessment and inclusion made before participation in&#xD;
             research&#xD;
&#xD;
          -  Membership or beneficiary of a social security scheme&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Language and French culture&#xD;
&#xD;
          -  study BAC level or equivalent&#xD;
&#xD;
          -  normal or corrected vision and hearing to normal&#xD;
&#xD;
          -  Inpatient and outpatient&#xD;
&#xD;
          -  diagnosis of schizophrenic disorders such deficit, paranoid and undifferentiated&#xD;
&#xD;
          -  clinical stability for three months with PANSS scores &lt;120 and no mood episode&#xD;
             characterized (MADRS &lt;15; YMRS &lt;12)&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Patient Refusal&#xD;
&#xD;
          -  neurological pathologies or progressive neurosurgical&#xD;
&#xD;
          -  psychiatric pathology addictive&#xD;
&#xD;
          -  Patients hospitalized under stress or under legal protection measure (guardianship,&#xD;
             curatorship)&#xD;
&#xD;
          -  Subject deprived of liberty by judicial or administrative decision&#xD;
&#xD;
          -  Contraindications to the practice of MRI equipment or incompatible metal or electronic&#xD;
             foreign body with MRI examination, permanent glasses, braces, Claustrophobia, cardiac&#xD;
             or neurological stimulator, Clip unsecured vascular nonmagnetic metal Eclat)&#xD;
&#xD;
          -  significant disorders of hearing and vision&#xD;
&#xD;
          -  Alcohol Ingestion&#xD;
&#xD;
          -  Pregnant women, women in labor, nursing mother&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AURELIE CAMPAGNE, PhD</last_name>
    <role>Study Director</role>
    <affiliation>LPNC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MIRCEA POLOSAN, PhD MD Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>GrenobleUniversityHospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VANESSA ESPIN</last_name>
    <phone>4 76 76 68 13</phone>
    <phone_ext>+33 (0)</phone_ext>
    <email>VEspin@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EMILIE COUSIN, PhD</last_name>
    <phone>0 13 63 86 45</phone>
    <email>cousin.emilie@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GrenobleUniversityHospital</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIRCEA POLOSAN, PhD MD Pr.</last_name>
      <phone>4 76 76 53</phone>
      <phone_ext>+33 (0)</phone_ext>
      <email>mpolosan@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>AURELIE CAMPAGNE, PhD</last_name>
      <phone>4 56 52 85 08</phone>
      <phone_ext>+33 (0)</phone_ext>
      <email>aurelie.campagne@univ-grenoble-alpes.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>emotional processing</keyword>
  <keyword>action</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

